MELAS Syndrome Clinical Trial
Official title:
Pilot Study to Investigate the Efficacy of L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome.
MELAS patients suffer from exercise intolerance, weakness, poor vision or blindness, poor growth, developmental delay, and deafness. They also have unique 'stroke-like' episodes (SLEs) which are not due to blockages of large or medium arteries. These 'strokes' are thought to be due to energy failure of very small brain blood vessels combined with energy failure in the mitochondria (cell battery) of the brain cells, especially in the back region of the brain in the vision centre. This leads to visual loss and paralysis. The overall goal of this study is to better understand the mechanism of these SLEs at the level of the brain cells and small blood vessels.
We will study a family of 3 siblings, each with different severities of MELAS, using safe, non-invasive tests. We will determine whether there is a decrease in the ability of small brain blood vessels to increase blood flow by dilating in response to certain stimuli such as increased blood carbon dioxide levels or in response to brain cell activation in the vision centre by visual stimuli. We will use a technique called BOLD-fMRI which can detect changes in brain blood flow. As exercising muscle also depends on increased blood flow and mitochondrial energy, we will study different measures of aerobic energy metabolism in exercising muscle using cycle exercise testing and special phosphorus-magnetic resonance spectroscopy which measures the changes in the major chemicals of muscle energy metabolism. The dietary amino acid L-arginine is known to dilate blood vessels increasing blood flow and to decrease toxic free radicals that are generated by dysfunctional mitochondria. We will determine the effect of a single dose and a 6 week trial of oral L-arginine, on brain blood vessel reactivity, brain cell activation and muscle aerobic function to see how useful this would be in the treatment of these patients and other mitochondrial disorders which present with strokes. ;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01831934 -
Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)
|
Phase 4 | |
| Not yet recruiting |
NCT06013397 -
Effectiveness of Ketogenic Diet in MELAS Syndrome
|
N/A | |
| Completed |
NCT04165239 -
The KHENERGYZE Study
|
Phase 2 | |
| Completed |
NCT00887562 -
Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis & Stroke-like Episodes
|
Phase 2 | |
| Active, not recruiting |
NCT00068913 -
Evaluating the Effectiveness of a Dichloroacetate in MELAS Syndrome
|
Phase 2 | |
| Completed |
NCT03888716 -
A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease
|
Phase 1 | |
| Completed |
NCT04948138 -
Glutamine Supplement in MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes) Syndrome
|
N/A | |
| Completed |
NCT03056209 -
Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers
|
Phase 1 | |
| Completed |
NCT01339494 -
Nitric Oxide Production in MELAS Syndrome
|
Phase 0 | |
| Active, not recruiting |
NCT05255328 -
Clinical Long Term Evaluation of Glutamine Supplement in MELAS Syndrome
|
N/A | |
| Recruiting |
NCT02114554 -
Mitochondrial nt3243 A>G Mutation in Taiwan
|
N/A | |
| Recruiting |
NCT05554835 -
Global Registry and Natural History Study for Mitochondrial Disorders
|
||
| Completed |
NCT01252979 -
Ketones & Mitochondrial Heteroplasmy
|
Phase 0 | |
| Completed |
NCT00004353 -
Study of the Metabolism of Pyruvate and Related Problems in Patients With Lactic Acidemia
|
N/A | |
| Recruiting |
NCT03952234 -
L-Citrulline Dose Finding Safety Study in MELAS
|
Phase 1 |